omeprazole has been researched along with Muscle Disorders in 5 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Polymyositis occurring in patients treated with omeprazole has been signalled as a possible adverse drug reaction (ADR) by the New Zealand Intensive Medicines Monitoring Programme (IMMP) and the WHO Collaborating Centre for International Drug Monitoring: the Uppsala Monitoring Centre (UMC)." | 4.83 | Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? ( Clark, DW; Strandell, J, 2006) |
| " Combining epidemiological studies with pharmacokinetic modeling, we detected and evaluated high-dimensional DDIs among 30 frequent drugs." | 1.48 | Translational High-Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models. ( Chiang, CW; Li, L; Ning, X; Quinney, SK; Shen, L; Wang, L; Wang, X; Zhang, P; Zhang, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiang, CW | 1 |
| Zhang, P | 1 |
| Wang, X | 1 |
| Wang, L | 1 |
| Zhang, S | 1 |
| Ning, X | 1 |
| Shen, L | 1 |
| Quinney, SK | 1 |
| Li, L | 1 |
| Tuccori, M | 1 |
| Giovannoni, S | 1 |
| Giustini, SE | 1 |
| Blandizzi, C | 1 |
| Del Tacca, M | 1 |
| Clark, DW | 1 |
| Strandell, J | 1 |
| Tröger, U | 1 |
| Stötzel, B | 1 |
| Martens-Lobenhoffer, J | 1 |
| Gollnick, H | 1 |
| Meyer, FP | 1 |
| Garrote, FJ | 1 |
| Lacambra, C | 1 |
| del Ser, T | 1 |
| García Díaz, B | 1 |
| Obeso, G | 1 |
| Solís, J | 1 |
1 review available for omeprazole and Muscle Disorders
| Article | Year |
|---|---|
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; | 2006 |
4 other studies available for omeprazole and Muscle Disorders
| Article | Year |
|---|---|
Translational High-Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models.
Topics: Adverse Drug Reaction Reporting Systems; Clonidine; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome | 2018 |
Acute severe myopathy following a single infusion of omeprazole.
Topics: Acute Disease; Aged; Humans; Infusions, Intravenous; Male; Muscular Diseases; Omeprazole; Proton Pum | 2006 |
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Benzimidazoles; Dermatologic Agents; Dru | 2002 |
Subacute myopathy during omeprazole therapy.
Topics: Aged; Electromyography; Female; Humans; Muscular Diseases; Omeprazole | 1992 |